Vinpocetine

2022-05-18: Nootropics reference: https://www.ergo-log.com/brain-works-better-after-two-days-of-vinpocetine.html https://www.longecity.org/forum/topic/23457-vinpocetine-ditch-it/

Vinpocetine #

• PDE1 inhibitor, improving peripheral Vasodilation.
• Compare to Ginkgo or Reserpine.
• Inhibits The NF-κB cascade via inhibiting IKK.
  • 
• Potent antioxidant. Used as a treatment for tinnitus.
• Reduces neuronal calcium influx without blocking presynaptic Ca2+ channels.
• [Effects of several cerebroprotective drugs on NMDA channel function: evaluation using Xenopus oocytes and [3H]MK-801 binding]
  • These results suggest that the inhibition of NMDA channels by vinpocetine shows a similarity to the action of Zn2+ which closes the gate of the NMDA channel
• Vinpocetine preferentially antagonizes quisqualate/AMPA receptor responses: evidence from release and ligand binding studies.
  • Reduced the efflux of dopamine and acetylcholine evoked by glutamate, quisqualate and NMDA, but not that evoked by kainate
• Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings
  • Raises DOPAC formation, at the expense of DA.
• Vinpocetine reduces cisplatin-induced acute kidney injury through inhibition of NF–κB pathway and activation of Nrf2/ARE pathway in rats
  • Seems to increase HO-1 and NF-κB inthis injury model unless I’m reading this wrong.
• Unique alterations to the rheological properties of Red Blood Cells. Reduced MDA and increased GSH levels in models of neurological damage
• Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings
  • Does not modify baseline DA release or exocytotic release evoked by K+; it inhibits DA release evoked by veratridine reversal of DAT.
  • Increases DOPAC levels suggesting an augmentation of dopamine metabolism, likely indepdendent of VSSC blockage, via increasing availability of the cytoplasm extravesicular DA; Impairs vesicular storage of Dopamine.
    • Does not enhance MAO, rather it acts like reserpine (VMAT2 inhibitor (it’s over)) which decreases the monoaminergic tone.
  • Inhibits voltage-gated sodium channel permeability, selectively inhibiting the transporter-mediated release of all neurotransmitters.
• [Vinpocetine and Ischemic Stroke]
  • Cerebral vasodilation enhances supply of oxygen & glucose, and ATP production.
• [Psychopharmacological Effects of Vinpocetine in Normal Healthy Volunteers]
  • Reported a lasting increase of cerebral 5-HIAA levels after treatment and transitorily enhanced 5-HT levels 2 h following (i.p.) treatment. Catecholamine levels were similarly increased 4-6 h following administration of vinpocetine.
  • Twelve females age 25-40 had dose-dependent decrease in reaction time in this memory test thing. Placebo 600 and plumetted from 560 to 420 after 20=>40mg.

Dosing #

• Absorption with food is 60-100% - fasting is ~6.7%.